Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
October 25, 2022 11:15 AM EDT
R&D

No­var­tis toss­es more US PD-1 sub­mis­sion plans and an­oth­er an­ti-CD40 drug in­di­ca­tion

Lei Lei Wu

News Reporter

Buried in No­var­tis’ third quar­ter re­port were a few key in­di­ca­tion drops.

First, No­var­tis is no longer plan­ning to sub­mit tislelizum­ab for FDA ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times